Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Aim: To examine sex differences in baseline characteristics and outcomes in patients with type 2 diabetes and atherosclerotic vascular disease. Materials and methods: Cox models were used to analyse the association between sex and outcomes in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), a randomized, placebo‐controlled trial assessing the impact of sitagliptin on cardiovascular (CV) outcomes in patients with type 2 diabetes and atherosclerotic vascular disease. Results: A total of 4297 women and 10 374 men were followed for a median of 3.0 years. Women were slightly older and more often had cerebrovascular disease and peripheral arterial disease but less often coronary heart disease than men. At baseline, women were less likely to use aspirin or statins. The primary composite outcome of CV death, myocardial infarction, stroke, or hospitalization for unstable angina occurred in 418 women (9.7%) and 1272 men (12.3%; 3.48 vs 4.38 events/100 participant‐years, crude hazard ratio [HR] 0.79, 95% confidence interval [CI] 0.71‐0.89, adjusted HR 0.64, 95% CI 0.55‐0.74; P < .0001). Women also had a significantly lower risk of secondary CV outcomes and all‐cause death. Conclusions: In this large prospective study of people with type 2 diabetes and CV disease, women had different CV disease burden, worse CV risk factor profiles, and less use of indicated medications than men. Despite this, women had significantly lower risk of CV events, suggesting that the cardioprotective effects of female sex extend to populations with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Self-citationEffect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577 · cited 2×
“In the publication of the primary TECOS results, no difference in the risk of major adverse CV events with sitagliptin compared with placebo was reported.(19) In the present, more comprehensive analyses of outcomes by sex, we have again found no suggestion of heterogeneity of the effects of sitagliptin therapy vs plac…”
BackgroundResultSelf-citationAlogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502 · cited 1×
“The observation that sitagliptin vs placebo had no significant effect on major adverse CV outcomes is consistent with findings from trials of other DPP-4 inhibitors, including saxagliptin and alogliptin.(28,29) However, no detailed sex-specific data have been published from those trials.”
ResultMortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes
and the WHO Multinational Study Group, Morrish, N. J., Wang, S.-L., Stevens, L. K., Fuller, J. H., & Keen, H. (2001) · Diabetologia · doi:10.1007/pl00002934 · Cited by 1,288 · cited 1×
“Diabetes is a strong risk factor for cardiovascular disease (CVD), and among people with type 2 diabetes, CVD is the leading cause of death.(3) Although women without diabetes have a lower risk of cardiovascular (CV) events than men, this advantage is reportedly lost in women with type 2 diabetes.”
BackgroundDiabetes and Decline in Heart Disease Mortality in US Adults
Gu, K. (1999) · JAMA · doi:10.1001/jama.281.14.1291 · Cited by 856
Peters, S. A. E., Huxley, R. R., & Woodward, M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60040-4 · Cited by 805
Peters, S. A. E., Huxley, R. R., & Woodward, M. (2014) · Diabetologia · doi:10.1007/s00125-014-3260-6 · Cited by 701
Risk factors that attenuate the female coronary disease advantage
Kannel, W. B. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.1995.00430010063008 · Cited by 381 · cited 1×
“Although women without diabetes have a lower risk of cardiovascular (CV) events than men, this advantage is reportedly lost in women with type 2 diabetes.(4,5) The INTERHEART case–control study(6) of participants with vs without myocardial infarction (MI), comprising >27 000 individuals from 52 countries, identified d…”
Hu, G., Jousilahti, P., Qiao, Q., Katoh, S., & Tuomilehto, J. (2005) · Diabetologia · doi:10.1007/s00125-005-1730-6 · Cited by 176 · cited 3×
“Several studies have confirmed a higher relative risk of CVD in women with vs without diabetes compared to men with vs without diabetes; however, the absolute risk of CVD in women with diabetes compared to men with diabetes has reportedly been higher,(8) similar, or lower.(5,13,14) Reported disparities in CV outcomes…”
BackgroundResultRoche, M. M., & Wang, P. P. (2013) · Diabetes Care · doi:10.2337/dc12-1272 · Cited by 113
Cited by
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Alonso, A., Beaton, A. Z., Bittencourt, M. S., Boehme, A. K., Buxton, A. E., Carson, A. P., Commodore-Mensah, Y., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001052 · Cited by 5,987
Heart Disease and Stroke Statistics—2021 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Aparicio, H. J., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Cheng, S., Delling, F. N., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000950 · Cited by 5,784
Martin, S. S., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Barone Gibbs, B., Beaton, A. Z., Boehme, A. K., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001209 · Cited by 2,800
Metadata
- Authors
- Alfredsson, J., Green, J. B., Stevens, S. R., Reed, S. D., Armstrong, P. W., Angelyn Bethel, M., Engel, S. S., McGuire, D. K., Van de Werf, F., Hramiak, I., White, H. D., Peterson, E. D., Holman, R. R., & on behalf of the TECOS Study Group
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2018-06-19
- Volume
- 20
- Issue
- 10
- Pages
- 2379-2388
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2809681611
- Cited by
- 59
- References
- 10
- FWCI
- 6.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS. https://app.cochat.ai/papers/10.1111/dom.13377
- The paper
- Alfredsson, J., Green, J. B., Stevens, S. R., Reed, S. D., Armstrong, P. W., Angelyn Bethel, M., Engel, S. S., McGuire, D. K., Van de Werf, F., Hramiak, I., White, H. D., Peterson, E. D., Holman, R. R., & on behalf of the TECOS Study Group. (2018). Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13377
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.